Ovary Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OVR059 MIFTS: 47	Ovary Adenocarcinoma Categories: Reproductive diseases, Rare diseases, Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma ¹² ¹⁵

Ovarian Adenocarcinoma ¹² ⁵⁹ ⁶ ⁷³

Adenocarcinoma of the Ovary ¹²

Adenocarcinoma of Ovary ⁵⁹

Ovarian Adenoacanthoma ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of ovary

Orphanet: ⁵⁹

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹² DOID:3713

NCIt ⁵⁰ C7700

Orphanet ⁵⁹ ORPHA213504

ICD10 via Orphanet ³⁴ C56

UMLS via Orphanet ⁷⁴ C0948216

UMLS ⁷³ C0948216

Sources

Summaries for Ovary Adenocarcinoma

Disease Ontology : ¹² An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to ovary serous adenocarcinoma and adenocarcinoma. An important gene associated with Ovary Adenocarcinoma is INHBA (Inhibin Subunit Beta A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Carboplatin and Nintedanib have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and placenta, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)

#	Related Disease	Score	Top Affiliating Genes
1	ovary serous adenocarcinoma	30.9	CEACAM5 HRAS KRAS ZNF217
2	adenocarcinoma	29.9	ERBB2 HRAS KRAS TP53
3	hepatocellular carcinoma	27.4	BAX CEACAM5 HRAS KRAS KRT7 TP53
4	clear cell adenocarcinoma of the ovary	12.3
5	mucinous adenocarcinoma of ovary	12.1
6	gastric papillary adenocarcinoma	10.8	ERBB2 TP53
7	uterine corpus serous adenocarcinoma	10.8	ERBB2 TP53
8	rare adenocarcinoma of the breast	10.7	KRAS TP53
9	oncocytic breast carcinoma	10.7	ERBB2 KRT7
10	female reproductive endometrioid cancer	10.7	KRT7 TP53
11	hyperplastic polyposis syndrome	10.7	KRAS TP53
12	eccrine sweat gland neoplasm	10.7	KRT7 TP53
13	non-proliferative fibrocystic change of the breast	10.7	ERBB2 TP53
14	uterine body mixed cancer	10.6	ARID1A ERBB2 TP53
15	schimmelpenning-feuerstein-mims syndrome	10.6	HRAS KRAS
16	periampullary adenoma	10.6	HRAS KRAS
17	apocrine adenocarcinoma	10.6	ERBB2 KRT7
18	paronychia	10.6	HRAS KRAS
19	oral cavity cancer	10.6	BAX ERBB2 TP53
20	small intestinal adenocarcinoma	10.6	BAX ERBB2 KRAS
21	mutyh-associated polyposis	10.6	KRAS TP53
22	spitz nevus	10.6	HRAS TP53
23	endometrioid ovary carcinoma	10.6	ARID1A POLE
24	ovarian benign neoplasm	10.6	KRT7 ZNF217
25	granulosa cell tumor of the ovary	10.5	ERBB2 KRT7 TP53
26	hidradenocarcinoma	10.5	ERBB2 KRT7 TP53
27	sweat gland cancer	10.5	ERBB2 KRT7 TP53
28	bladder carcinoma in situ	10.5	KRT7 TP53
29	ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3	10.5	ARID1A KRAS TP53
30	bile duct cysts	10.5	HRAS KRAS
31	barrett's adenocarcinoma	10.5	ERBB2 KRAS TP53
32	clear cell adenocarcinoma	10.5	ARID1A KRT7 TP53
33	cervical adenocarcinoma	10.5	ERBB2 KRT7 TP53
34	pleomorphic adenoma carcinoma	10.5	ERBB2 TP53
35	breast mucoepidermoid carcinoma	10.4	CEACAM5 ERBB2
36	pseudomyxoma peritonei	10.4	KRAS KRT7 TP53
37	serous cystadenocarcinoma	10.4	ERBB2 HRAS TP53
38	acneiform dermatitis	10.4	ERBB2 HRAS KRAS
39	intracystic papillary adenoma	10.4	CEACAM5 ERBB2
40	adenosquamous carcinoma	10.4	KRAS KRT7 TP53
41	adenosquamous cell lung carcinoma	10.4	ERBB2 HRAS KRAS
42	mucoepidermoid esophageal carcinoma	10.4	CEACAM5 TP53
43	epithelial-myoepithelial carcinoma	10.4	HRAS KRT7 TP53
44	exanthem	10.4	ERBB2 HRAS KRAS
45	cutaneous mucoepidermoid carcinoma	10.4	CEACAM5 KRT7
46	anal gland adenocarcinoma	10.4	CEACAM5 KRT7
47	intracranial chondrosarcoma	10.4	CEACAM5 TP53
48	anal canal adenocarcinoma	10.4	HRAS KRAS KRT7
49	liver angiosarcoma	10.4	HRAS KRAS TP53
50	ampulla of vater neoplasm	10.3	HRAS KRAS KRT7

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:

Sources

Symptoms & Phenotypes for Ovary Adenocarcinoma

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 45)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	9.94	KRAS
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-115	9.94	INHBA
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.94	KRAS
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	9.94	ZNF217
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	9.94	POLE
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-127	9.94	ZNF217
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-131	9.94	ZNF217
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-147	9.94	ZNF217
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.94	ZNF217
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-159	9.94	ZNF217
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.94	ERBB2 ZNF217
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-163	9.94	ERBB2
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.94	POLE ERBB2 KRAS
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.94	KRAS
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	9.94	ZNF217
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-194	9.94	INHBA
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-196	9.94	KRAS
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	9.94	POLE
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	9.94	POLE ERBB2
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-23	9.94	KRAS
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	9.94	ZNF217
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.94	POLE ERBB2
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	9.94	KRAS
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	9.94	KRAS
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.94	POLE ERBB2 INHBA KRAS ZNF217
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-67	9.94	ZNF217
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.94	INHBA
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	9.94	ZNF217
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.94	POLE ERBB2
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	9.94	KRAS
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	9.94	ZNF217
32	Decreased shRNA abundance (Z-score < -2)	GR00366-A-1	9.91	POLE
33	Decreased shRNA abundance (Z-score < -2)	GR00366-A-104	9.91	ZNF217
34	Decreased shRNA abundance (Z-score < -2)	GR00366-A-148	9.91	ERBB2 ZNF217
35	Decreased shRNA abundance (Z-score < -2)	GR00366-A-155	9.91	ZNF217
36	Decreased shRNA abundance (Z-score < -2)	GR00366-A-173	9.91	ZNF217
37	Decreased shRNA abundance (Z-score < -2)	GR00366-A-191	9.91	ZNF217
38	Decreased shRNA abundance (Z-score < -2)	GR00366-A-216	9.91	ZNF217
39	Decreased shRNA abundance (Z-score < -2)	GR00366-A-28	9.91	HRAS
40	Decreased shRNA abundance (Z-score < -2)	GR00366-A-60	9.91	ERBB2
41	Decreased shRNA abundance (Z-score < -2)	GR00366-A-68	9.91	HRAS
42	Decreased shRNA abundance (Z-score < -2)	GR00366-A-77	9.91	ZNF217
43	Decreased shRNA abundance (Z-score < -2)	GR00366-A-87	9.91	POLE ERBB2 HRAS ZNF217
44	Decreased shRNA abundance (Z-score < -2)	GR00366-A-91	9.91	POLE
45	Decreased shRNA abundance (Z-score < -2)	GR00366-A-95	9.91	HRAS

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	9.86	ERBB2 HRAS INHBA KRAS ACSBG1 TP53
2	neoplasm	MP:0002006	9.7	ERBB2 HRAS KRAS POLE TP53 ARID1A
3	reproductive system	MP:0005389	9.56	ERBB2 INHBA KRAS TP53 ACSBG1 ARID1A
4	skeleton	MP:0005390	9.23	ERBB2 HRAS INHBA KRAS TP53 ARID1A

Sources

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 2

41575-94-4

10339178 498142 38904

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

azanide

Blastocarb

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

Carbopaltin

Carboplat

carboplatin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Carbosin

Carbotec

Cbdca

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

Cyclobutane-1,1-dicarboxylate

cyclobutane-1,1-dicarboxylic acid

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

Ercar

EU-0100230

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

IUPAC: Azane

JM 8

JM8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

Lopac0_000230

Lopac-C-2538

LS-117689

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

Nealorin

Neocarbo

NINDS_000892

NSC 201345

NSC 241240

NSC201345

NSC241240

NSC-241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

platinum(2+)

Platinum(II), (1, 1-cyclobutanedicar

Platinum, {diammine[1,1-cyclobut

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Ribocarbo

S1215_Selleck

SPBio_000716

Spectrum_001529

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

UNII-BG3F62OND5

Nintedanib

Approved

Phase 2

656247-17-5

56843413

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Bevacizumab

Approved, Investigational

Phase 2,Phase 1

216974-75-3

Synonyms:

216974-75-3

antiVEGF

anti-VEGF monoclonal antibody

Avastin

Avastin (TN)

bevacizumab

Bevacizumab

Bevacizumab (genetical recombination)

Bevacizumab (genetical recombination) (JAN)

bevacizumab-awwb

D06409

R-435

nivolumab

Approved

Phase 2

946414-94-4

Romidepsin

Approved, Investigational

Phase 2

128517-07-7

5352062

Synonyms:

(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone

(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

128517-07-7

AC1NS1N3

Antibiotic FR 901228

C087123

C24H36N4O6S2

CHEBI:61080

CHEMBL343448

Chromadax

Chromadax (TN)

chromodax

CID5352062

Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3?5)-disulfide"

D06637

FK 228

FK228

FK-228

FK-901228

FR 901228

FR901228

FR-901228

HDInhib_000006

Istodax

LS-161318

L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide

nchembio.313-comp2

NSC 630176

NSC630176

NSC-630176

Probes1_000153

Probes2_000337

Romidepsin

Romidepsin (USAN)

Aldesleukin

Approved

Phase 2

85898-30-2, 110942-02-4

Dianhydrogalactitol

Investigational

Phase 1, Phase 2

23261-20-3

Vaccines

Phase 1, Phase 2,Phase 2

Albumin-Bound Paclitaxel

Phase 2,Phase 1

Antimitotic Agents

Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 2,Phase 1

Antibodies

Phase 2

Immunoglobulins

Phase 2

Pharmaceutical Solutions

Phase 2

Antibodies, Monoclonal

Phase 2

Alkylating Agents

Phase 1, Phase 2

Antineoplastic Agents, Alkylating

Phase 1, Phase 2

Anti-Bacterial Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Adjuvants, Immunologic

Phase 2

Anti-HIV Agents

Phase 2

Anti-Infective Agents

Phase 2

Anti-Retroviral Agents

Phase 2

Antiviral Agents

Phase 2

Freund's Adjuvant

Phase 2

Cisplatin

Approved

Phase 1

15663-27-1

84093 441203 2767

Synonyms:

(SP-4-1)-diamminedichloridoplatinum

(SP-4-1)-diamminedichloroplatinum

(SP-4-2)-diamminedichloridoplatinum

(SP-4-2)-diamminedichloroplatinum

Abiplatin

Biocisplatinum

Briplatin

CACP

Carboquone

CDDP

CHEBI:35852

CID441203

Cis Pt II

cis-[PtCl2(NH3)2]

cis-DDP

Cis-DDP

Cis-Diaminedichloroplatinum

cis-diamminedichloridoplatinum(II)

cis-Diamminedichloroplatinum

Cis-Diamminedichloroplatinum

cis-diamminedichloroplatinum(II)

cis-Dichlorodiammineplatinum(II)

Cismaplat

Cisplatine

Cisplatino

Cisplatinum

Cisplatyl

Citoplationo

CPD0-1392

CPDC

CPDD

DB00515

DDP

DDPT

Diamminedichloroplatinum

EU-0100918

Lederplatin

nchembio773-comp1

Neoplatin

Peyrone's chloride

Peyrone's salt

Plastin

Platamine

Platiblastin

Platidiam

Platinex

Platinol

Platinol-AQ

Platinoxan

Platinum Ammine Chloride

Platinum Ammonium Chloride

Platinum Diamine Dichloride

Randa

trans-DDP

Trans-DDP

Trans-Diaminedichloroplatinum

trans-diamminedichloridoplatinum(II)

Trans-Diamminedichloroplatinum

Trans-Dichlorodiammine Platinum

Trans-Platinumdiammine Dichloride

CHI3L1 protein, human

Interventional clinical trials:

(show all 15)

#	Name	Status	NCT ID	Phase	Drugs
1	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	Completed	NCT00243685	Phase 2, Phase 3
2	Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer	Unknown status	NCT00660101	Phase 1, Phase 2
3	Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer	Completed	NCT01583322	Phase 2	vargatef;placebo
4	Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients	Completed	NCT00127920	Phase 2	Avastin
5	PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies	Recruiting	NCT03365791	Phase 2
6	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
7	A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer	Not yet recruiting	NCT03281681	Phase 1, Phase 2	VAL-083, Dianhydrogalactitol
8	Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer	Terminated	NCT00091195	Phase 2	romidepsin
9	p53 Vaccine for Ovarian Cancer	Terminated	NCT00001827	Phase 2
10	Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma	Completed	NCT02217956	Phase 1	Cisplatin;Bevacizumab
11	Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients	Completed	NCT00562003	Phase 1	Ad5-delta24RGD
12	Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer	Completed	NCT02195973	Phase 1	LDE225
13	Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment	Terminated	NCT00585845	Phase 1
14	The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients	Recruiting	NCT03019315
15	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy	Terminated	NCT00899093

Search NIH Clinical Center for Ovary Adenocarcinoma

Sources

Genetic Tests for Ovary Adenocarcinoma

Sources

Anatomical Context for Ovary Adenocarcinoma

MalaCards organs/tissues related to Ovary Adenocarcinoma:

⁴¹

Ovary, Endothelial, Placenta, Thyroid, Liver, Colon

Sources

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 91)

#	Title	Authors	Year
1	Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( 29117515 )	Rogalska A....Marczak A.	2018
2	Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3. ( 28714011 )	Zou B....Wang Y.	2017
3	Sister Mary Joseph Nodule in an Ovary Adenocarcinoma. ( 28790552 )	Poparic S....Kapetanovic A.	2017
4	A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas. ( 26992853 )	Mittal K....Aneja R.	2016
5	Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression. ( 25971681 )	Chen P.X....Yang Z.	2015
6	KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries. ( 25028599 )	Pawar S....Aneja R.	2014
7	Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. ( 23707658 )	Chen P.X....Yang Z.	2013
8	What is your diagnosis? Ovarian adenocarcinoma. ( 24344516 )	Delk K.W....Nietfeld J.	2013
9	Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. ( 22826464 )	Takahashi Y....Sato Y.	2012
10	Paraneoplastic hypercalcemia in clear cell ovarian adenocarcinoma. ( 23056149 )	Lewin S....Klein P.	2012
11	CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma. ( 20571827 )	Miyake T....Kimura T.	2011
12	Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma. ( 20730571 )	Lee H.J....Ahn W.S.	2011
13	Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis. ( 20514505 )	Yamano T....Aozasa K.	2010
14	Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. ( 20673788 )	Nourbakhsh M....Karami-Tehrani F.	2010
15	Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. ( 20728204 )	Scheil-Bertram S....Fisseler-Eckhoff A.	2010
16	External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. ( 19775429 )	Partheen K....Horvath G.	2009
17	Malignant pericardial effusion with cardiac tamponade in ovarian adenocarcinoma. ( 19225795 )	Petersen E.E....Goodheart M.J.	2009
18	Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. ( 19174584 )	Hakim A.A....Rodriguez G.C.	2009
19	Dermatan sulfate domains defined by the novel antibody GD3A12, in normal tissues and ovarian adenocarcinomas. ( 19360434 )	ten Dam G.B....Van Kuppevelt T.H.	2009
20	Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. ( 20044634 )	Turunen M....Santala M.	2009
21	[Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma]. ( 19090447 )	Petersen M....Lippert H.	2009
22	Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. ( 19426511 )	Fedorowicz G....Modrusan Z.	2009
23	cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. ( 18554190 )	Linnerth N.M....Moorehead R.A.	2008
24	CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling. ( 18082618 )	Watanabe Y....Shiota G.	2008
25	Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. ( 18097583 )	Yasuda M....Osamura R.Y.	2008
26	Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. ( 18709641 )	Partheen K....Horvath G.	2008
27	Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas. ( 17885491 )	Levidou G....Patsouris E.	2007
28	MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. ( 17713092 )	Cirpan T....Sagol S.	2007
29	Tight junction formation in epithelial ovarian adenocarcinoma. ( 17653889 )	Zhu Y....Sundfeldt K.	2007
30	CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. ( 16942793 )	Jackson E....Mozdziak P.E.	2007
31	Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report. ( 17977179 )	Micha J.P....Brown J.V.	2007
32	Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma. ( 18041444 )	Larbcharoensub N....Rochanawutanon M.	2007
33	Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. ( 17319785 )	SolA!r P....Fedorocko P.	2007
34	Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. ( 17538174 )	Birrer M.J....Mok S.C.	2007
35	Cell surface overexpression of alphavbeta5 integrin impedes alphavbeta3-mediated migration of the human ovarian adenocarcinoma cell line IGROV1. ( 17074516 )	Maubant S....Gauduchon P.	2007
36	Carcinomatous lymphangitis as the initial manifestation of ovarian adenocarcinoma. ( 18026661 )	Martynychen M.G....Escuissato D.L.	2007
37	Mucinous carcinoma of thyroid gland. Report of a primary and a metastatic mucinous tumour from ovarian adenocarcinoma with immunohistochemical study and review of literature. ( 17704943 )	D'Antonio A....Nappi O.	2007
38	Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. ( 16897186 )	Kanoh A....Yamashita K.	2006
39	Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. ( 16996261 )	Partheen K....Horvath G.	2006
40	Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas. ( 15870720 )	Gubbay O....Hillier S.G.	2005
41	Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. ( 15900302 )	Arnold J.M....Chenevix-Trench G.	2005
42	Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. ( 16203778 )	Tsuda H....Mok S.C.	2005
43	Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. ( 15609323 )	Leroy-Dudal J....Carreiras F.	2005
44	Adhesion of human ovarian adenocarcinoma IGROV1 cells to endothelial cells is partly mediated by the alphav integrins-vitronectin adhesive system and induces an alteration of endothelial integrity. ( 15914035 )	Leroy-Dudal J....Carreiras F.	2005
45	Role of estrogen and progesterone in the survival of ovarian tumors--a study of the human ovarian adenocarcinoma cell line OC-117-VGH. ( 16138714 )	Chao K.C....Chi C.W.	2005
46	Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. ( 14766248 )	Torng P.L....Lin C.T.	2004
47	COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. ( 15492238 )	Dornan D....French D.M.	2004
48	Ovarian tumor expression of an oviductal protein in the hen: a model for human serous ovarian adenocarcinoma. ( 15581958 )	Giles J.R....Johnson P.A.	2004
49	[Relationship between expression of hyaluronan and pathologic features of ovarian adenocarcinoma]. ( 14960239 )	Qu J.Y....Wang Y.Q.	2004
50	Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. ( 12648589 )	Konstantinidou A.E....Davaris P.	2003

Sources

Genes for Ovary Adenocarcinoma

Genes related to Ovary Adenocarcinoma (1 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	INHBA	Inhibin Subunit Beta A	Protein Coding	350	Causative germline mutation ⁵⁹
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	29.23	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵
3	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	16.89	GeneCards inferred via : Expressions (show sections)
4	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	15.82	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	ESS2	Ess-2 Splicing Factor Homolog	Protein Coding	15.79	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	TP53	Tumor Protein P53	Protein Coding	15.54	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
7	KRT7	Keratin 7	Protein Coding	15.4	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	15.26	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
9	ZNF217	Zinc Finger Protein 217	Protein Coding	15.13	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	15.04	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	ARL11	ADP Ribosylation Factor Like GTPase 11	Protein Coding	14.95	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
12	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	14.81	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
13	ASTL	Astacin Like Metalloendopeptidase	Protein Coding	14.69	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
14	C1RL	Complement C1r Subcomponent Like	Protein Coding	7.23	GeneCards inferred via : Expressions (show sections)
15	CEACAM5	Carcinoembryonic Antigen Related Cell Adhesion Molecule 5	Protein Coding	6.32	DISEASES inferred ¹⁵
16	ACSBG1	Acyl-CoA Synthetase Bubblegum Family Member 1	Protein Coding	6.2	DISEASES inferred ¹⁵
17	PTGES3L-AARSD1	PTGES3L-AARSD1 Readthrough	Protein Coding	5.2	DISEASES inferred ¹⁵

Sources

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	ERBB2	NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28933370	GRCh37	Chromosome 17, 37881378: 37881378
2	ERBB2	NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28933370	GRCh38	Chromosome 17, 39725125: 39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	118124	17	7571720	7590868	Mutation	TP53	Ovarian adenocarcinomas

Sources

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Sources

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 38)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.9	BAX ERBB2 HRAS KRAS TP53
2	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.75	BAX ERBB2 HRAS KRAS TP53
3	Pathways in cancer ³⁷	12.72	BAX ERBB2 HRAS KRAS TP53
4	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.65	BAX ERBB2 HRAS KRAS TP53
5	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.58	BAX ERBB2 HRAS KRAS TP53
6	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.51	ARID1A BAX ERBB2 HRAS KRAS TP53
7	Kaposi's sarcoma-associated herpesvirus infection ³⁷ Show member pathways Hepatitis B ³⁷	12.49	BAX HRAS KRAS TP53
8	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.45	ERBB2 HRAS KRAS TP53
9	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.43	BAX ERBB2 HRAS KRAS TP53
10	MicroRNAs in cancer ³⁷	12.42	ERBB2 HRAS KRAS TP53
11	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.4	ERBB2 HRAS KRAS TP53
12	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.38	BAX ERBB2 HRAS KRAS
13	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.37	ERBB2 HRAS KRAS TP53
14	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.25	BAX ERBB2 HRAS KRAS TP53
15	HTLV-I infection ³⁷	12.21	BAX HRAS KRAS POLE TP53
16	Proteoglycans in cancer ³⁷	12.17	ERBB2 HRAS KRAS TP53
17	Viral carcinogenesis ³⁷	12.16	BAX HRAS KRAS TP53
18	NGF Pathway ⁶⁴ Show member pathways TRKA Signaling ⁶⁴	12.01	BAX HRAS KRAS TP53
19	Longevity regulating pathway ³⁷ Show member pathways Longevity regulating pathway - multiple species ³⁷	11.99	BAX HRAS KRAS TP53
20	Ceramide Pathway ⁶⁴ Show member pathways TNF-Induced Apoptosis Implicating Sphingolipids ⁶⁴	11.94	BAX HRAS KRAS
21	Thyroid hormone signaling pathway ³⁷	11.91	HRAS KRAS TP53
22	Glioblastoma Multiforme ⁶⁴	11.88	HRAS KRAS TP53
23	AKT Signaling Pathway ⁶⁷	11.87	BAX ERBB2 HRAS KRAS TP53
24	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.86	ERBB2 HRAS KRAS
25	Senescence and Autophagy in Cancer ¹	11.85	HRAS INHBA TP53
26	Sphingolipid signaling pathway ³⁷	11.83	BAX HRAS KRAS TP53
27	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.81	BAX HRAS KRAS
28	VEGF Pathway (Tocris) ⁷² Show member pathways Sorafenib Pharmacodynamics ⁶¹	11.7	BAX HRAS KRAS
29	Platinum drug resistance ³⁷	11.63	BAX ERBB2 TP53
30	Mitophagy - animal ³⁷	11.56	HRAS KRAS TP53
31	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.46	ERBB2 HRAS KRAS
32	Bladder cancer ³⁷ ¹	11.42	ERBB2 HRAS KRAS TP53
33	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.28	ARID1A ERBB2 HRAS TP53
34	Transcription_Transcription factor Tubby signaling pathways ²²	11.23	HRAS KRAS TP53
35	Extracellular vesicle-mediated signaling in recipient cells ¹	11.13	ERBB2 HRAS KRAS
36	DNA Damage Response (only ATM dependent) ¹	11.08	BAX ERBB2 HRAS KRAS TP53
37	Central carbon metabolism in cancer ³⁷	11.07	ERBB2 HRAS KRAS TP53
38	p38MAPK events ⁶⁶	10.74	HRAS KRAS

Sources

GO Terms for Ovary Adenocarcinoma

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nervous system development	GO:0007399	9.8	ARID1A BAX ERBB2 ESS2 INHBA
2	positive regulation of gene expression	GO:0010628	9.55	ERBB2 HRAS INHBA KRAS TP53
3	Ras protein signal transduction	GO:0007265	9.54	HRAS KRAS TP53
4	positive regulation of protein oligomerization	GO:0032461	9.46	BAX TP53
5	positive regulation of extrinsic apoptotic signaling pathway in absence of ligand	GO:2001241	9.43	BAX INHBA
6	positive regulation of MAP kinase activity	GO:0043406	9.43	ERBB2 HRAS KRAS
7	response to isolation stress	GO:0035900	9.32	HRAS KRAS
8	ERBB2 signaling pathway	GO:0038128	9.13	ERBB2 HRAS KRAS
9	intrinsic apoptotic signaling pathway	GO:0097193	8.8	BAX HRAS TP53

Molecular functions related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleotide binding	GO:0000166	9.02	ACSBG1 ERBB2 HRAS KRAS POLE

Sources

Sources for Ovary Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia